CA2886757C - Treatment of anxiety with il1.alpha. antagonist - Google Patents

Treatment of anxiety with il1.alpha. antagonist Download PDF

Info

Publication number
CA2886757C
CA2886757C CA2886757A CA2886757A CA2886757C CA 2886757 C CA2886757 C CA 2886757C CA 2886757 A CA2886757 A CA 2886757A CA 2886757 A CA2886757 A CA 2886757A CA 2886757 C CA2886757 C CA 2886757C
Authority
CA
Canada
Prior art keywords
antibody
monoclonal antibody
human
pharmaceutical composition
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2886757A
Other languages
English (en)
French (fr)
Other versions
CA2886757A1 (en
Inventor
John Simard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Biotech Inc
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of CA2886757A1 publication Critical patent/CA2886757A1/en
Application granted granted Critical
Publication of CA2886757C publication Critical patent/CA2886757C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
CA2886757A 2012-10-04 2013-10-01 Treatment of anxiety with il1.alpha. antagonist Active CA2886757C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261709741P 2012-10-04 2012-10-04
US61/709,741 2012-10-04
PCT/US2013/062899 WO2014055541A1 (en) 2012-10-04 2013-10-01 Treatment of psychiatric conditions

Publications (2)

Publication Number Publication Date
CA2886757A1 CA2886757A1 (en) 2014-04-10
CA2886757C true CA2886757C (en) 2022-04-05

Family

ID=50435375

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2886757A Active CA2886757C (en) 2012-10-04 2013-10-01 Treatment of anxiety with il1.alpha. antagonist

Country Status (7)

Country Link
EP (1) EP2903643A4 (https=)
JP (3) JP6750941B2 (https=)
KR (1) KR20150064091A (https=)
CN (1) CN104684581A (https=)
AU (1) AU2013327498B2 (https=)
CA (1) CA2886757C (https=)
WO (1) WO2014055541A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102167261B1 (ko) 2010-06-18 2020-10-20 엑스바이오테크, 인크. 관절염 치료
US10294296B2 (en) 2010-08-23 2019-05-21 Xbiotech, Inc. Treatment for neoplastic diseases
US9724409B2 (en) 2011-04-01 2017-08-08 Xbiotech, Inc. Treatment of inflammatory skin disease
ES2695102T3 (es) 2011-09-23 2019-01-02 Xbiotech Inc Tratamiento para la caquexia
US9545441B2 (en) 2012-09-18 2017-01-17 Xbiotech, Inc. Treatment of diabetes
CA3053231A1 (en) * 2017-02-16 2018-08-23 Xbiotech Inc. Treatment of hidradenitis suppurativa
CA3095740A1 (en) 2020-10-07 2022-04-07 Xbiotech Inc. True human antibody specific for interleukin alpha (il-1a)
CA3095675A1 (en) 2020-10-07 2022-04-07 Xbiotech Inc. True human antibody specific for interleukin 1 alpha (il-1a)
CA3095676A1 (en) 2020-10-07 2022-04-07 Xbiotech Inc. True human antibody specific for interleukin 1 alpha (il-1a)
CA3095679A1 (en) 2020-10-07 2022-04-07 Xbiotech Inc. True human antibody specific for interleuken 1 alpha (il-1a)
WO2024095677A1 (ja) 2022-11-04 2024-05-10 パナソニック インテレクチュアル プロパティ コーポレーション オブ アメリカ 端末、基地局、通信方法及び集積回路

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5959085A (en) * 1993-11-23 1999-09-28 Schering Corporation Human monoclonal antibodies against human cytokines and methods of making and using such antibodies
GB9405021D0 (en) * 1994-03-15 1994-04-27 Unilever Plc Skin treatment composition
US5455234A (en) * 1994-03-16 1995-10-03 Ahluwalia; Gurpreet S. Inhibition of hair growth
JP2002226457A (ja) * 2001-02-02 2002-08-14 Ajinomoto Co Inc 新規シスチン誘導体及び炎症因子活性化抑制剤
CA2726345C (en) * 2008-05-30 2018-08-28 John Simard Interleukin-1 alpha antibodies and methods of use
SG172855A1 (en) * 2009-01-29 2011-08-29 Abbott Lab Il-1 binding proteins
US9724409B2 (en) * 2011-04-01 2017-08-08 Xbiotech, Inc. Treatment of inflammatory skin disease
JP6062918B2 (ja) * 2011-04-01 2017-01-18 エックスバイオテク, インコーポレイテッドXbiotech, Inc. 皮膚科的病理の治療

Also Published As

Publication number Publication date
JP2022177132A (ja) 2022-11-30
EP2903643A1 (en) 2015-08-12
KR20150064091A (ko) 2015-06-10
JP2015531396A (ja) 2015-11-02
JP2020143133A (ja) 2020-09-10
EP2903643A4 (en) 2016-06-15
AU2013327498A1 (en) 2015-04-02
JP6750941B2 (ja) 2020-09-02
CA2886757A1 (en) 2014-04-10
CN104684581A (zh) 2015-06-03
WO2014055541A1 (en) 2014-04-10
AU2013327498B2 (en) 2018-06-28

Similar Documents

Publication Publication Date Title
US11191831B2 (en) Treatment of psychiatric conditions
CA2886757C (en) Treatment of anxiety with il1.alpha. antagonist
AU2017201201B2 (en) Treatment for dermatological pathologies
US12116405B2 (en) Arthritis treatment
HK40013773A (zh) 皮肤病学病状的治疗
HK1187260A (en) Treatment for dermatological pathologies

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20180928

H11 Ip right ceased following rejected request for revival

Free format text: ST27 STATUS EVENT CODE: T-6-6-H10-H11-H101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TIME LIMIT FOR REVERSAL EXPIRED

Effective date: 20250403